Selective Targeting of T Cells to Tumors using Precision TwoGATE™ (Guided Antibody Tumor Engagers)

Time: 12:30 pm
day: Day Two


  • Traditional T cell engagers bring T cells in close proximity of tumors and drive potent tumor cell killing. Despite the highly potent nature of these agents, their clinical utility is limited by off-target and on-target/off-tumor toxicities
  • Revitope’s two-component bi-specific TwoGATE ™ platform aims to address these key liabilities by incorporating several design features to more specifically focus T cell redirection to the tumor including requirements for dual antigen expression in the tumor, tumor protease driven cleavage and activation, and a built in PK switch to limit systemic exposure of GATE™ once activated in the tumor